Literature DB >> 7272932

Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data.

C Fabian, L Sternson, M El-Serafi, L Cain, E Hearne.   

Abstract

Blood tamoxifen levels were determined for patients with metastatic breast cancer following initial and chronic dosing at twice daily 10 mg/m2 or a 20 mg/m2 single dose. Median time to response was six weeks. Blood tamoxifen levels at that time were ten-fold greater than those obtained after an initial single dose; however, steady-state values were not achieved until 16 weeks of chronic dosing. On a loading dose schedule of 40 mg/m2 twice daily for seven days and 20 mg/m2 daily thereafter, blood levels greater than or equal to 10 mg/m2 twice daily steady-state values were reached in one week. Levels drawn at peak and trough times suggest that tamoxifen may be given on a once-daily basis. Tamoxifen half-life was 9-12 hours after the initial dose and seven days after chronic dosing.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7272932     DOI: 10.1002/1097-0142(19810815)48:4<876::aid-cncr2820480403>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.

Authors:  Kathryn E Weaver; Fabian Camacho; Wenke Hwang; Roger Anderson; Gretchen Kimmick
Journal:  Am J Clin Oncol       Date:  2013-04       Impact factor: 2.339

2.  Tumor and serum tamoxifen concentrations in the athymic nude mouse.

Authors:  M W DeGregorio; E Coronado; C K Osborne
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.

Authors:  E Petru; D Schmähl
Journal:  Klin Wochenschr       Date:  1987-10-15

4.  Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial.

Authors:  Stephanie R Land; Walter M Cronin; D Lawrence Wickerham; Joseph P Costantino; Nicholas J Christian; William M P Klein; Patricia A Ganz
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-23

5.  Treatment of advanced breast cancer.

Authors:  C L Sinoff
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-05

6.  The bioavailability of Tamoplex (tamoxifen). Part 3. A steady-state study in breast cancer patients.

Authors:  P H Slee; D De Vos; D Chapman; D Stevenson
Journal:  Pharm Weekbl Sci       Date:  1988-02-19

7.  Immuno-biochemical assay for determination of nuclear steroid receptors during tamoxifen therapy.

Authors:  A Vering; A Vockel; M Stegmüller; H G Bender
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 8.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

9.  Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

Authors:  Stephanie R Land; Farzana L Walcott; Qing Liu; D Lawrence Wickerham; Joseph P Costantino; Patricia A Ganz
Journal:  J Natl Cancer Inst       Date:  2015-11-27       Impact factor: 13.506

10.  Tamoxifen (Nolvadex) therapy--radionale for loading dose followed by maintenance dose for patients with metastatic breast cancer.

Authors:  P M Wilkinson; G G Ribiero; H K Adam; J V Kemp; J S Patterson
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.